Related references
Note: Only part of the references are listed.Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation
Lena Hell et al.
CANCERS (2021)
Disseminated Intravascular Coagulation in Cancer: An Update
Marcel Levi
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies
Chrysoula Papageorgiou et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H. Schroder et al.
BJU INTERNATIONAL (2010)
Procoagulant mechanisms in tumour cells
Anna Falanga et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Disseminated intravascular coagulation: What's new?
M Levi
CRITICAL CARE CLINICS (2005)
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
FB Taylor et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Share Paper
